ghk-cu hair growth clinical trial randomized GHK Peptide (2016) — Research Summary This peptide reverses aging..., And

Prescribing information (Eli Lilly, 2025)

Multiple clinical trials in photoaged skin (sun damage) have shown that topical GHK-Cu formulations improve skin appearance including reductions in fine lines and wrinkles, improvement in skin firmness and elasticity, enhancement of skin texture and smoothness, increase in skin thickness (reversing age-related dermal atrophy), improvement in skin clarity and reduction in hyperpigmentation, and overall rejuvenated appearance

18, Hurley, A., & Frier, A

Petrelintide (ZP8396) Petrelintide (ZP8396) is a novel SC-administered, long-acting amylin analog, developed by Zealand Pharma (Sborg, Denmark), a peptide drug discovery and development company, which is currently in early-stage clinical trials (phase 1 clinical trials: ClinicalTrials.gov Identifier NCT05511025, NCT05096598 and NCT05613387) [116]